A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

Evan M Hersh, Steven J. O'Day, John Powderly, Khuda D. Khan, Anna C. Pavlick, Lee D Cranmer, Wolfram E. Samlowski, Geoffrey M. Nichol, Michael J. Yellin, Jeffrey S. Weber

Research output: Contribution to journalArticle

208 Citations (Scopus)

Abstract

Objective: Ipilimumab is a fully human, anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that has demonstrated antitumor activity in advanced melanoma. We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma. Methods: Chemotherapy-naïve patients were randomized in this multicenter, phase II study to receive ipilimumab at 3 mg/kg every 4 weeks for four doses either alone or with up to six 5-day courses of DTIC at 250 mg/m2/day. The primary efficacy endpoint was objective response rate. Results: Seventy-two patients were treated per-protocol (ipilimumab plus DTIC, n=35; ipilimumab, n=37). The objective response rate was 14.3% (95% CI, 4.8-30.3) with ipilimumab plus DTIC and was 5.4% (95% CI, 0.7-18.2) with ipilimumab alone. At a median follow-up of 20.9 and 16.4 months for ipilimumab plus DTIC (n=32) and ipilimumab alone (n=32), respectively, median overall survival was 14.3 months (95% CI, 10.2-18.8) and 11.4 months (95% CI, 6.1-15.6); 12-month, 24-month, and 36-month survival rates were 62%, 24% and 20% for the ipilimumab plus DTIC group and were 45%, 21% and 9% for the ipilimumab alone group, respectively. Immune-related adverse events were, in general, medically manageable and occurred in 65.7% of patients in the combination group versus 53.8% in the monotherapy group, with 17.1% and 7.7% ≥grade 3, respectively. Conclusion: Ipilimumab therapy resulted in clinically meaningful responses in advanced melanoma patients, and the results support further investigations of ipilimumab in combination with DTIC.

Original languageEnglish (US)
Pages (from-to)489-498
Number of pages10
JournalInvestigational New Drugs
Volume29
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Dacarbazine
Multicenter Studies
Melanoma
Drug Therapy
ipilimumab
CTLA-4 Antigen

Keywords

  • CTLA-4
  • Dacarbazine
  • Immune therapy
  • Ipilimumab
  • Metastatic melanoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. / Hersh, Evan M; O'Day, Steven J.; Powderly, John; Khan, Khuda D.; Pavlick, Anna C.; Cranmer, Lee D; Samlowski, Wolfram E.; Nichol, Geoffrey M.; Yellin, Michael J.; Weber, Jeffrey S.

In: Investigational New Drugs, Vol. 29, No. 3, 06.2011, p. 489-498.

Research output: Contribution to journalArticle

Hersh, Evan M ; O'Day, Steven J. ; Powderly, John ; Khan, Khuda D. ; Pavlick, Anna C. ; Cranmer, Lee D ; Samlowski, Wolfram E. ; Nichol, Geoffrey M. ; Yellin, Michael J. ; Weber, Jeffrey S. / A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. In: Investigational New Drugs. 2011 ; Vol. 29, No. 3. pp. 489-498.
@article{db6c786f4a9f49d5837ba8535501cd69,
title = "A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na{\"i}ve patients with advanced melanoma",
abstract = "Objective: Ipilimumab is a fully human, anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that has demonstrated antitumor activity in advanced melanoma. We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma. Methods: Chemotherapy-na{\"i}ve patients were randomized in this multicenter, phase II study to receive ipilimumab at 3 mg/kg every 4 weeks for four doses either alone or with up to six 5-day courses of DTIC at 250 mg/m2/day. The primary efficacy endpoint was objective response rate. Results: Seventy-two patients were treated per-protocol (ipilimumab plus DTIC, n=35; ipilimumab, n=37). The objective response rate was 14.3{\%} (95{\%} CI, 4.8-30.3) with ipilimumab plus DTIC and was 5.4{\%} (95{\%} CI, 0.7-18.2) with ipilimumab alone. At a median follow-up of 20.9 and 16.4 months for ipilimumab plus DTIC (n=32) and ipilimumab alone (n=32), respectively, median overall survival was 14.3 months (95{\%} CI, 10.2-18.8) and 11.4 months (95{\%} CI, 6.1-15.6); 12-month, 24-month, and 36-month survival rates were 62{\%}, 24{\%} and 20{\%} for the ipilimumab plus DTIC group and were 45{\%}, 21{\%} and 9{\%} for the ipilimumab alone group, respectively. Immune-related adverse events were, in general, medically manageable and occurred in 65.7{\%} of patients in the combination group versus 53.8{\%} in the monotherapy group, with 17.1{\%} and 7.7{\%} ≥grade 3, respectively. Conclusion: Ipilimumab therapy resulted in clinically meaningful responses in advanced melanoma patients, and the results support further investigations of ipilimumab in combination with DTIC.",
keywords = "CTLA-4, Dacarbazine, Immune therapy, Ipilimumab, Metastatic melanoma",
author = "Hersh, {Evan M} and O'Day, {Steven J.} and John Powderly and Khan, {Khuda D.} and Pavlick, {Anna C.} and Cranmer, {Lee D} and Samlowski, {Wolfram E.} and Nichol, {Geoffrey M.} and Yellin, {Michael J.} and Weber, {Jeffrey S.}",
year = "2011",
month = "6",
doi = "10.1007/s10637-009-9376-8",
language = "English (US)",
volume = "29",
pages = "489--498",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

AU - Hersh, Evan M

AU - O'Day, Steven J.

AU - Powderly, John

AU - Khan, Khuda D.

AU - Pavlick, Anna C.

AU - Cranmer, Lee D

AU - Samlowski, Wolfram E.

AU - Nichol, Geoffrey M.

AU - Yellin, Michael J.

AU - Weber, Jeffrey S.

PY - 2011/6

Y1 - 2011/6

N2 - Objective: Ipilimumab is a fully human, anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that has demonstrated antitumor activity in advanced melanoma. We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma. Methods: Chemotherapy-naïve patients were randomized in this multicenter, phase II study to receive ipilimumab at 3 mg/kg every 4 weeks for four doses either alone or with up to six 5-day courses of DTIC at 250 mg/m2/day. The primary efficacy endpoint was objective response rate. Results: Seventy-two patients were treated per-protocol (ipilimumab plus DTIC, n=35; ipilimumab, n=37). The objective response rate was 14.3% (95% CI, 4.8-30.3) with ipilimumab plus DTIC and was 5.4% (95% CI, 0.7-18.2) with ipilimumab alone. At a median follow-up of 20.9 and 16.4 months for ipilimumab plus DTIC (n=32) and ipilimumab alone (n=32), respectively, median overall survival was 14.3 months (95% CI, 10.2-18.8) and 11.4 months (95% CI, 6.1-15.6); 12-month, 24-month, and 36-month survival rates were 62%, 24% and 20% for the ipilimumab plus DTIC group and were 45%, 21% and 9% for the ipilimumab alone group, respectively. Immune-related adverse events were, in general, medically manageable and occurred in 65.7% of patients in the combination group versus 53.8% in the monotherapy group, with 17.1% and 7.7% ≥grade 3, respectively. Conclusion: Ipilimumab therapy resulted in clinically meaningful responses in advanced melanoma patients, and the results support further investigations of ipilimumab in combination with DTIC.

AB - Objective: Ipilimumab is a fully human, anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody that has demonstrated antitumor activity in advanced melanoma. We evaluated the safety and efficacy of ipilimumab alone and in combination with dacarbazine (DTIC) in patients with unresectable, metastatic melanoma. Methods: Chemotherapy-naïve patients were randomized in this multicenter, phase II study to receive ipilimumab at 3 mg/kg every 4 weeks for four doses either alone or with up to six 5-day courses of DTIC at 250 mg/m2/day. The primary efficacy endpoint was objective response rate. Results: Seventy-two patients were treated per-protocol (ipilimumab plus DTIC, n=35; ipilimumab, n=37). The objective response rate was 14.3% (95% CI, 4.8-30.3) with ipilimumab plus DTIC and was 5.4% (95% CI, 0.7-18.2) with ipilimumab alone. At a median follow-up of 20.9 and 16.4 months for ipilimumab plus DTIC (n=32) and ipilimumab alone (n=32), respectively, median overall survival was 14.3 months (95% CI, 10.2-18.8) and 11.4 months (95% CI, 6.1-15.6); 12-month, 24-month, and 36-month survival rates were 62%, 24% and 20% for the ipilimumab plus DTIC group and were 45%, 21% and 9% for the ipilimumab alone group, respectively. Immune-related adverse events were, in general, medically manageable and occurred in 65.7% of patients in the combination group versus 53.8% in the monotherapy group, with 17.1% and 7.7% ≥grade 3, respectively. Conclusion: Ipilimumab therapy resulted in clinically meaningful responses in advanced melanoma patients, and the results support further investigations of ipilimumab in combination with DTIC.

KW - CTLA-4

KW - Dacarbazine

KW - Immune therapy

KW - Ipilimumab

KW - Metastatic melanoma

UR - http://www.scopus.com/inward/record.url?scp=79955581263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955581263&partnerID=8YFLogxK

U2 - 10.1007/s10637-009-9376-8

DO - 10.1007/s10637-009-9376-8

M3 - Article

C2 - 20082117

AN - SCOPUS:79955581263

VL - 29

SP - 489

EP - 498

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -